We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
In the latest trading session, Vertex Pharmaceuticals (VRTX - Free Report) closed at $408.85, marking a +1.15% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.06%. Elsewhere, the Dow saw an upswing of 0.17%, while the tech-heavy Nasdaq appreciated by 0.39%.
Heading into today, shares of the drugmaker had gained 1.91% over the past month, lagging the Medical sector's gain of 5.06% and the S&P 500's gain of 3.94%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company is forecasted to report an EPS of $4.56, showcasing a 4.11% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.04 billion, up 9.78% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.98 per share and a revenue of $11.98 billion, signifying shifts of +4180.95% and +8.75%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Vertex Pharmaceuticals is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 22.48. Its industry sports an average Forward P/E of 19.2, so one might conclude that Vertex Pharmaceuticals is trading at a premium comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 73, this industry ranks in the top 30% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Vertex Pharmaceuticals (VRTX - Free Report) closed at $408.85, marking a +1.15% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.06%. Elsewhere, the Dow saw an upswing of 0.17%, while the tech-heavy Nasdaq appreciated by 0.39%.
Heading into today, shares of the drugmaker had gained 1.91% over the past month, lagging the Medical sector's gain of 5.06% and the S&P 500's gain of 3.94%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company is forecasted to report an EPS of $4.56, showcasing a 4.11% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.04 billion, up 9.78% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.98 per share and a revenue of $11.98 billion, signifying shifts of +4180.95% and +8.75%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Vertex Pharmaceuticals is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 22.48. Its industry sports an average Forward P/E of 19.2, so one might conclude that Vertex Pharmaceuticals is trading at a premium comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 73, this industry ranks in the top 30% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.